Silmara Mendes Martins Moulin1, Frederico Jacob Eutrópio2, Jessica de Oliveira Souza1, Fernanda de Oliveira Busato3, David N Olivieri4, Carlos Eduardo Tadokoro5,6. 1. Programa de Pós-graduação em Ciências Farmacêuticas (PPGCF), Universidade Vila Velha, R. José Mauro de Vasconcelos, s/n, Laboratory of Immunobiology, room #33, Vila Velha, ES, 29107-530, Brazil. 2. Programa de Pós-Graduação em Ecologia de Ecossistemas (PPGEE, UVV), Instituto Capixaba de Ciência e Administração (ICCA), Vila Velha, ES, Brazil. 3. Laboratory of Immunobiology, Universidade Vila Velha, Vila Velha, ES, Brazil. 4. Escuela Superior de Ingeniería Informatica, University of Vigo, Vigo, Spain. 5. Programa de Pós-graduação em Ciências Farmacêuticas (PPGCF), Universidade Vila Velha, R. José Mauro de Vasconcelos, s/n, Laboratory of Immunobiology, room #33, Vila Velha, ES, 29107-530, Brazil. carlos.tadokoro@uvv.br. 6. Laboratory of Immunobiology, Universidade Vila Velha, Vila Velha, ES, Brazil. carlos.tadokoro@uvv.br.
Abstract
PURPOSE: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease, accounting for 15 to 20% of leukemias, with an incidence of one to two cases/100,000 inhabitants. In Brazil, the estimated incidence of leukemia is six cases/100,000 men and 4.28 cases/100,000 women. CML is characterized by the presence of the Philadelphia chromosome. At present, three types of tyrosine kinase inhibitors (TKI) are administered to treat CML patients in the Brazilian public national health system (NHS), called the Unified Health System (in Portuguese, "Sistema Único de Saúde", SUS). Such treatments are only effective if patients adhere to strict dosage regimens; protocol improvements that increase patient adherence to treatment would have economic and health benefits for overburdened health care systems. Here, pharmacist-monitored treatment is assessed. METHODS: In our study, we applied two questionnaires, one to assess the adherence to pharmacological treatment and another to assess the quality of life. All patients studied (n = 23) were diagnosed with CML at a local hospital in "Espírito Santo" State, the "Hospital Evangélico Vila Velha" (HEVV). RESULTS: Treatment adherence was significantly higher in pharmacist-monitored patients than in nonmonitored patients (p = 0.0135). The quality of life of CML patients was also analyzed, indicating that monitored patients had a lower number of symptoms/complaints during treatment periods than nonmonitored patients. Finally, improved treatment adherence also translated into better clinical conditions, particularly during the early stage of treatment (e.g., the first 4 months). CONCLUSIONS: The intervention of a clinical pharmacist is significant to obtain positive clinical results. Therefore, it is recommended that this protocol be included in the standard NHS treatment protocol CML patient outcomes to reduce the indirect and recurring costs to the health care system caused by nonadherence.
PURPOSE:Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease, accounting for 15 to 20% of leukemias, with an incidence of one to two cases/100,000 inhabitants. In Brazil, the estimated incidence of leukemia is six cases/100,000 men and 4.28 cases/100,000 women. CML is characterized by the presence of the Philadelphia chromosome. At present, three types of tyrosine kinase inhibitors (TKI) are administered to treat CMLpatients in the Brazilian public national health system (NHS), called the Unified Health System (in Portuguese, "Sistema Único de Saúde", SUS). Such treatments are only effective if patients adhere to strict dosage regimens; protocol improvements that increase patient adherence to treatment would have economic and health benefits for overburdened health care systems. Here, pharmacist-monitored treatment is assessed. METHODS: In our study, we applied two questionnaires, one to assess the adherence to pharmacological treatment and another to assess the quality of life. All patients studied (n = 23) were diagnosed with CML at a local hospital in "Espírito Santo" State, the "Hospital Evangélico Vila Velha" (HEVV). RESULTS: Treatment adherence was significantly higher in pharmacist-monitored patients than in nonmonitored patients (p = 0.0135). The quality of life of CMLpatients was also analyzed, indicating that monitored patients had a lower number of symptoms/complaints during treatment periods than nonmonitored patients. Finally, improved treatment adherence also translated into better clinical conditions, particularly during the early stage of treatment (e.g., the first 4 months). CONCLUSIONS: The intervention of a clinical pharmacist is significant to obtain positive clinical results. Therefore, it is recommended that this protocol be included in the standard NHS treatment protocol CMLpatient outcomes to reduce the indirect and recurring costs to the health care system caused by nonadherence.
Authors: Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers Journal: N Engl J Med Date: 2006-06-15 Impact factor: 91.245
Authors: Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman Journal: Blood Date: 2006-03-07 Impact factor: 22.113
Authors: Hagop M Kantarjian; Francis Giles; Norbert Gattermann; Kapil Bhalla; Giuliana Alimena; Francesca Palandri; Gert J Ossenkoppele; Franck-Emmanuel Nicolini; Stephen G O'Brien; Mark Litzow; Ravi Bhatia; Francisco Cervantes; Ariful Haque; Yaping Shou; Debra J Resta; Aaron Weitzman; Andreas Hochhaus; Philipp le Coutre Journal: Blood Date: 2007-08-22 Impact factor: 22.113
Authors: Jessica de O Souza; Fernanda de O Busato; Isadora Duarte Santos Frota; Daniel Santos Neves; Marcelo Renan de Deus Santos; David N Olivieri; Carlos E Tadokoro Journal: Support Care Cancer Date: 2017-11-18 Impact factor: 3.603
Authors: Shoshana M Rosenberg; Keith J Petrie; Annette L Stanton; Lan Ngo; Emma Finnerty; Ann H Partridge Journal: J Natl Cancer Inst Date: 2020-05-01 Impact factor: 13.506
Authors: Thiago R Santos; Jonathan Penm; André O Baldoni; Lorena Rocha Ayres; Rebekah Moles; Cristina Sanches Journal: Hum Resour Health Date: 2018-01-04